Holen Sie sich die Stockscreener-App
1.75
12.50%
-0.25
Handel nachbörslich:
1.85
0.10
+5.71%
Schlusskurs vom Vortag:
$2.00
Offen:
$2
24-Stunden-Volumen:
66,384
Relative Volume:
0.51
Marktkapitalisierung:
$14.66M
Einnahmen:
$2.38M
Nettoeinkommen (Verlust:
$-12.40M
KGV:
-0.2708
EPS:
-6.4626
Netto-Cashflow:
$-18.68M
1W Leistung:
-13.37%
1M Leistung:
-37.05%
6M Leistung:
-77.96%
1J Leistung:
-85.71%
1-Tages-Spanne:
$1.71
$2.02
1-Wochen-Bereich:
$1.71
$2.15
52-Wochen-Spanne:
$1.71
$22.20
Femasys Inc Stock (FEMY) Company Profile
Firmenname
Femasys Inc
Sektor
Telefon
770-500-3910
Adresse
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, RMD, MDLN, ALC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.75 | 14.66M | 2.38M | -12.40M | -18.68M | -6.4626 |
ISRG
Intuitive Surgical Inc
|
427.64 | 151.08B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.89 | 51.45B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
234.60 | 32.99B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.76 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
64.35 | 31.11B | 10.63B | 819.00M | 1.59B | 1.6577 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Laidlaw | Buy |
Femasys Inc Aktie (FEMY) Neueste Nachrichten
Form 4 Femasys Inc For: 29 September By Investing.com - Investing.com Nigeria
Femasys Inc (NASDAQ: FEMY) Share Price, FEMY Stock News, FEMY Share Price & Updates - Kalkine
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio - Yahoo Finance
Femasys Company Profile & Introduction - Moomoo
Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value - GuruFocus
FemasysFiles For Resale Of Up To 28,124,997 Shares Of Common StockSEC Filing - TradingView
Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan
Femasys Inc (FEMY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Stonepine group flags new Femasys (NASDAQ: FEMY) position investors will want to size - Stock Titan
Femasys (FEMY) Stock News & Analysis - TechStock²
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com India
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com Canada
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com UK
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations - The Manila Times
Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayValue Stock Ideas - vinanet.vn
Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayComposite Profile - dars.gov.et
Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingVolume Dry Up - vinanet.vn
Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingHagopian Line - siam.in
Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest TradingVolatility Smirk - vinanet.vn
Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan
Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm
Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com
Why Is Femasys Stock Soaring Today?Femasys (NASDAQ:FEMY) - Benzinga
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Stocktwits
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - TradingView
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionLow Growth Earnings - Vinanet
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance
Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com
FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com India
Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record
Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - marketscreener.com
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Yahoo Finance
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionAnalyst Coverage Count - dars.gov.et
Femasys secures $30 million to advance fertility portfolio - The Pharma Letter
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan
FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31%Earnings Turnaround - vinanet.vn
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us
Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade
Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan
Femasys reports $331,827 Q2 revenue, $4.47M net loss and $30M financing to support U.S. commercial push - TradingView
Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss - Quiver Quantitative
Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing - Stock Titan
Femasys 2Q Loss/Shr $1.33 >FEMY - Moomoo
Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Finanzdaten der Femasys Inc-Aktie (FEMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Femasys Inc-Aktie (FEMY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sipos Jeremy Alexander | Chief Technology Officer |
Aug 07 '26 |
Buy |
3.20 |
3,125 |
10,000 |
3,125 |
| Canning John Charles | Chief Operating Officer |
Aug 07 '26 |
Buy |
3.20 |
4,375 |
14,000 |
4,375 |
| Elefant Dov | Chief Financial Officer |
Aug 07 '26 |
Buy |
3.20 |
15,625 |
50,000 |
15,625 |
| Lee-Sepsick Kathy | Chief Executive Officer |
Aug 07 '26 |
Buy |
3.20 |
15,625 |
50,000 |
15,625 |
21.89%
6.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):